Table 1 Demographic Data of Patients with and without a PE

Demographics

Age (yr), median (IQR)

Males

Females

BMI (kg/m²), median (IQR)

59 (49-71)

40 (61)

26 (39)

28.6 (24.6-35.0)

64.5 (52.8-71)

48 (52)

44 (48)

27.6 (23.4-33.2)

62.5 (49.3-71.0)

88 (56)

70 (44)

28 (23.7-33.9)

0.40

0.37

0.32

Race

Black or African American

Hispanic

White

Asian

Others

18 (27)

15 (23)

22 (33)

0 (0)

11 (17)

24 (26)

22 (24)

12 (13)

9 (10)

25 (27)

42 (27)

37 (23)

34 (22)

9 (6)

36 (23)

0.002

Comorbidities

Hypertension

Diabetes

Hyperlipidemia

Active malignancy

COPD/asthma

Coronary artery disease

Congestive heart failure

Atrial fibrillation

Chronic kidney disease

Chronic liver disease

Cerebrovascular accident

Myocardial infarction

Autoimmune disease

Previous gastrointestinal bleed

Prior DVT/PE

Oral contraceptive pill use

25 (38)

17 (26)

19 (29)

6 (9)

6 (9)

8 (12)

2 (3)

3 (5)

4 (6)

1 (2)

5 (8)

1 (2)

7 (11)

0 (0)

7 (11)

0 (0)

50 (54)

24 (26)

31 (34)

16 (17)

22 (24)

17 (19)

9 (10)

8 (9)

10 (11)

4 (4)

9 (10)

6 (7)

8 (9)

4 (4)

12 (13)

1 (1)

75 (48)

41 (26)

50 (32)

22 (14)

28 (18)

25 (16)

11 (7)

11 (7)

14 (9)

5 (3)

14 (9)

7 (6)

15 (10)

4 (3)

19 (12)

1 (1)

0.05

1.00

0.63

0.21

0.03

0.39

0.18

0.36

0.40

0.40

0.84

0.24

0.90

0.14

0.83

1.00

Smoking

No

46 (70)

62 (67)

108 (68)

0.89

Active/prior

20 (30)

30 (33)

50 (32)

Family history of DVT/PE

2 (3)

0 (0)

2 (1)

0.17

History suggestive of hyper-coagulable state

2 (3)

7 (8)

9 (6)

0.31

Recent surgery / immobilization

8 (12)

4 (4)

12 (8)

0.12

Chronic home anticoagulation

None

Lovenox/DOAC/coumadin

Antiplatelet

DAPT

63 (96)

3 (5)

9 (14)

1 (2)

83 (90)

9 (10)

20 (22)

3 (3)

146 (92)

12 (8)

29 (18)

4 (3)

0.36

0.28

0.64

Prophylactic anticoagulation

0.046

Prophylactic LMWH

Therapeutic LMWH

UFH

DOAC

34 (37)

4 (4)

19 (21)

8 (9)

14 (21)

6 (9)

12 (18)

4 (6)

48 (30)

10 (60)

30 (20)

12 (76)

Length of stay (mean days)

14.6

13.7

0.158

Severity of parenchymal lung disease

None

Mild

Moderate

Severe

10

27

20

9

12

30

30

20

0.817

0.394